We want to share some great news for all our Adjuvant Patients! Health Canada has just approved the use of a combination therapy of Tafinlar® (dabrafenib) plus Mekinist® (trametinib) to prevent recurrence of melanoma following surgery in patients with a stage II or stage III diagnosis, also referred to as ‘adjuvant’ treatment. Click below to read our full press release.
GREAT NEWS: HEALTH CANADA APPROVES FI... - Melanoma Wellness...
GREAT NEWS: HEALTH CANADA APPROVES FIRST ADJUVANT TREATMENT FOR MELANOMA TO PREVENT RELAPSE FOLLOWING SURGERY!
Written by
amykjones
Administrator
To view profiles and participate in discussions please or .
Read more about...
1 Reply
•
nataliemelanomaAdministratorSYSF AmbassadorSYSF
This is great news indeed. But now we have to hope (and wait) to see this approved in each province and territory.